PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX??? Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Stock Information for PolyPid Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PolyPid Ltd.

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX??? SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
PolyPid to Participate in The Citizens Life Sciences Conference
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX??? for the Prevention of Abdominal Colorectal Surgical Site Infections

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.